Titre
Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Marroquin Belaunzaran, O.
Auteure/Auteur
Cordero, M.I.
Auteure/Auteur
Setola, V.
Auteure/Auteur
Bianchi, S.
Auteure/Auteur
Galli, C.
Auteure/Auteur
Bouche, N.
Auteure/Auteur
Mlynarik, V.
Auteure/Auteur
Gruetter, R.
Auteure/Auteur
Sandi, C.
Auteure/Auteur
Bensadoun, J.C.
Auteure/Auteur
Molinari, M.
Auteure/Auteur
Aebischer, P.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1932-6203
Statut éditorial
Publié
Date de publication
2011
Volume
6
Numéro
4
Première page
e18268
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: epublish
Résumé
BACKGROUND: Monoclonal antibodies and antibody fragments are powerful biotherapeutics for various debilitating diseases. However, high production costs, functional limitations such as inadequate pharmacokinetics and tissue accessibility are the current principal disadvantages for broadening their use in clinic.
METHODOLOGY AND PRINCIPAL FINDINGS: We report a novel method for the long-term delivery of antibody fragments. We designed an allogenous immunoisolated implant consisting of polymer encapsulated myoblasts engineered to chronically release scFv antibodies targeted against the N-terminus of the Aβ peptide. Following a 6-month intracerebral therapy we observed a significant reduction of the production and aggregation of the Aβ peptide in the APP23 transgenic mouse model of Alzheimer's disease. In addition, functional assessment showed prevention of behavioral deficits related to anxiety and memory traits.
CONCLUSIONS AND SIGNIFICANCE: The chronic local release of antibodies using immunoisolated polymer cell implants represents an alternative passive vaccination strategy in Alzheimer's disease. This novel technique could potentially benefit other diseases presently treated by local and systemic antibody administration.
METHODOLOGY AND PRINCIPAL FINDINGS: We report a novel method for the long-term delivery of antibody fragments. We designed an allogenous immunoisolated implant consisting of polymer encapsulated myoblasts engineered to chronically release scFv antibodies targeted against the N-terminus of the Aβ peptide. Following a 6-month intracerebral therapy we observed a significant reduction of the production and aggregation of the Aβ peptide in the APP23 transgenic mouse model of Alzheimer's disease. In addition, functional assessment showed prevention of behavioral deficits related to anxiety and memory traits.
CONCLUSIONS AND SIGNIFICANCE: The chronic local release of antibodies using immunoisolated polymer cell implants represents an alternative passive vaccination strategy in Alzheimer's disease. This novel technique could potentially benefit other diseases presently treated by local and systemic antibody administration.
PID Serval
serval:BIB_2D8D929616D2
PMID
Open Access
Oui
Date de création
2013-04-29T08:41:43.661Z
Date de création dans IRIS
2025-05-20T14:25:08Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
BIB_2D8D929616D2.P001.pdf
Version du manuscrit
preprint
Taille
1.6 MB
Format
Adobe PDF
PID Serval
serval:BIB_2D8D929616D2.P001
URN
urn:nbn:ch:serval-BIB_2D8D929616D21
Somme de contrôle
(MD5):7ed4cf7ae970ee87a6977e46915c4d9a